Nanometronomics: doxorubicin-loaded H-ferritin allows for tailored treatment of breast cancer based on lower doses and higher safety

Michela Bellini

Università degli Studi di Milano-Bicocca

Michela Bellini, PhD student in Life Science at the University of Milan-Bicocca, Italy. She received her bachelor degree in Pharmaceutical Biotechnology in 2008 and her master degree in Chemistry and Pharmaceutical Technology in 2013, at the University of Milan, Italy. From 2013 she works at the NanoBioLab, Department of Biotechnology and Biosciences (University of Milan-Bicocca) and in 2014 she starts her PhD program, carrying out her research activity focused on the development of apoferritin nanoparticles as drug delivery system for cancer therapy, especially breast cancer.


The standard clinical approach for cancer chemotherapy is based on the concept of maximum tolerated dose (MTD) of drug for a patient. This strategy, however, presents several disadvantages, including major systemic toxicity... [ view full abstract ]


  1. Serena Mazzucchelli (Università degli Studi di Milano)
  2. Michela Bellini (Università degli Studi di Milano-Bicocca)
  3. Marta Truffi (Università degli Studi di Milano)
  4. Luisa Fiandra (Università degli Studi di Milano)
  5. Maria Antonietta Rizzuto (Università degli Studi di Milano-Bicocca)
  6. Luca Sorrentino (Università degli Studi di Milano)
  7. Fabio Corsi (Università degli Studi di Milano)
  8. Davide Prosperi (Università degli Studi di Milano-Bicocca)

Topic Areas

Targeted drug delivery and Nanocarriers , Nanomedecine for cancer diagnosis & therapy


OS1-025 » Targeted drug delivery and Nanocarriers - Nanomedecine for cancer diagnosis & therapy (16:00 - Wednesday, 28th September, Amphitheatre 25)

Presentation Files

The presenter has not uploaded any presentation files.